Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
By Jorge Marrero, L. Kulik, Claude B. Sirlin, Andrew X. Zhu, R. Finn, Michael M. Abecassis, Lewis R. Roberts, J. Heimbach. Clinical Liver Disease, 2019
3,139 citations recorded by the source corpus.
and Scope This guidance provides a data-supported approach to the diagnosis, staging, and treatment of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is different from a guideline. Guidelines are developed by a multidisciplinary panel of experts who rate the quality (level) of the evidence and the strength of each recommendation using the Grading of Recommendations Assessment, Development, and Evaluation system (GRADE). A guidance document is developed by a panel of experts in the topic, and guidance statements, not recommendations, are put forward to help clinicians understand and implement the most recent evidence. which The focused and treatment of HCC. However, some areas of HCC lacked sufficient data to perform systematic reviews, and here the authors will the 2010 American Association the Study of Diseases Guidelines, hereto referred as the guidance for HCC. biopsy has a risk of bleeding, tumor seeding, and the pos-sibility that a negative biopsy is attributed to the failure to obtain tissue representative of the nodule rather than a truly benign nodule. first-line of subjects carcinoma
Subfields: Cancer Research, Hepatology, Oncology
View Paper: https://www.semanticscholar.org/paper/fa19a79772fab610421b19283ce12c42015670e7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hepatology
Citations in the corpus
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023, neutral): “[101,102] In these patients (Figure 6), arterial phase hyperenhancement (APHE) and washout on portal venous or delayed phases of contrast-enhanced multiphase CT or MRI are considered radiological hallmarks of HCC given high specificity and positive predictive value in lesions ≥ 1 cm in size.”
- Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. (2018, methodology): “This report provides an overview of LI-RADS and its application in practice, including changes introduced in the most recent update (version 2018) required for harmonization with the AASLD.”